UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
| (Check
one): |
☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form
10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form
N-CSR |
| |
For
Period Ended: June 30, 2025 |
| |
☐ Transition
Report on Form 10-K |
| |
☐ Transition
Report on Form 20-F |
| |
☐ Transition
Report on Form 11-K |
| |
☐ Transition
Report on Form 10-Q |
| |
For
the Transition Period Ended: |
| |
___________________________________ |
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I – REGISTRANT INFORMATION
TNF
Pharmaceuticals, Inc.
Full
Name of Registrant
N/A
Former
Name if Applicable
1185 Avenue of the Americas. Suite 249
Address
of Principal Executive Office (Street and Number)
New York, NY 10036
City,
State and Zip Code
PART
II – RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
| |
(a) |
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense |
| ☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
| |
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III – NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period.
TNF
Pharmaceuticals, Inc. (the “Company”) is unable to file, without unreasonable effort and expense, its Quarterly Report on
Form 10-Q for the six months ended June 30, 2025 (the “Form 10-Q”), because the Company requires additional time to complete
and finalize its financial statements required to be included in the Form 10-Q. The Company currently anticipates that the Form 10-Q
will be filed on or before the fifth calendar day following the prescribed due date.
PART
IV – OTHER INFORMATION
| (1) |
Name
and telephone number of person to contact in regard to this notification |
| Joshua
Silverman |
|
856 |
|
848-8698 |
| (Name) |
|
(Area
Code) |
|
(Telephone
Number) |
| (2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). Yes ☒ No ☐ |
| |
|
| |
|
| (3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? |
| |
Yes ☐ No ☒ |
| |
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
TNF
Pharmaceuticals, Inc.
(Name
of registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
| Date:
|
August
14, 2025 |
|
By:
|
/s/
Joshua Silverman |
| |
|
|
Name:
|
Joshua
Silverman |
| |
|
|
Title: |
Director |
